A Tale of Two Vaccines: Lessons from Polio That Could Inform the Development of an HIV Vaccine
Overview
Authors
Affiliations
Two vaccine trials that were conducted 50 years apart are reviewed and compared: the 1954 field trial of the Salk inactivated polio vaccine and the RV144 HIV vaccine trial conducted in Thailand between 2003 and 2009. Despite the obvious differences in science and historical periods, several lessons were identified that could inform the future HIV vaccine effort. Those lessons are related to paradigm changes that occur when science progresses, the need to test scientific hypothesis in efficacy trials, the controversies surrounding those trials, the need for strong community and political support, the participation of government and nongovernment institutions, the balance between implementation of other preventive and therapeutic interventions, and the priority given by society to develop a vaccine. If we have the humility and courage to apply some of those lessons, we may be able accelerate the development of an urgently needed HIV vaccine.
Immunological evaluation of an inactivated SARS-CoV-2 vaccine in rhesus macaques.
Chen H, Xie Z, Long R, Fan S, Li H, He Z Mol Ther Methods Clin Dev. 2021; 23:108-118.
PMID: 34462721 PMC: 8387130. DOI: 10.1016/j.omtm.2021.08.005.
Hicks R, Johnson S, Porter A, Zatzick D J Neurotrauma. 2017; 34(19):2833-2839.
PMID: 28351324 PMC: 5647496. DOI: 10.1089/neu.2016.4821.
Barmania S, Aljunid S BMC Public Health. 2016; 16:524.
PMID: 27387326 PMC: 4936207. DOI: 10.1186/s12889-016-3247-y.
What Has 30 Years of HIV Vaccine Research Taught Us?.
Esparza J Vaccines (Basel). 2015; 1(4):513-26.
PMID: 26344345 PMC: 4494212. DOI: 10.3390/vaccines1040513.